QILIAN INTERNATIONAL HOLDING GROUP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.61 USD | +18.75% |
|
-6.96% | -6.40% |
| Jun. 04 | Qilian International Holding Group Limited Announces Board and Committee Changes | CI |
| Jun. 04 | Qilian International Holding Group Limited Announces Chief Financial Officer Changes | CI |
Financials (USD)
| Sales 2022 | 64.86M | Sales 2023 | 46.47M | Capitalization | 28.14M |
|---|---|---|---|---|---|
| Net income 2022 | 1M | Net income 2023 | -7M | EV / Sales 2022 | 0.46 x |
| Net cash position 2022 | 12.55M | Net cash position 2023 | 21.84M | EV / Sales 2023 | 0.14 x |
| P/E ratio 2022 |
39.7
x | P/E ratio 2023 |
-3.58
x | Employees | 298 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 33.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +18.75% | ||
| 1 week | -6.96% | ||
| Current month | -9.75% | ||
| 1 month | -7.45% | ||
| 3 months | +4.65% | ||
| 6 months | +58.72% | ||
| Current year | -6.40% |
1 week
2.80
3.80
1 month
2.804.99
Current year
1.784.99
1 year
1.784.99
3 years
1.7822.50
5 years
1.78110.00
10 years
1.78110.00
| Managers | Title | Age | Since |
|---|---|---|---|
Zhan Chang Xin
CEO | Chief Executive Officer | 58 | 19-02-06 |
Hai Ping Shi
DFI | Director of Finance/CFO | 51 | 20-04-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Song Gao
BRD | Director/Board Member | 56 | 23-07-12 |
Zhan Chang Xin
CEO | Chief Executive Officer | 58 | 19-02-06 |
Hai Ping Shi
DFI | Director of Finance/CFO | 51 | 20-04-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-28 | 3.61 | +18.75% | 44 986 |
| 24-06-27 | 3.04 | -0.33% | 26,956 |
| 24-06-26 | 3.05 | -5.57% | 60,059 |
| 24-06-25 | 3.23 | -5.00% | 56,570 |
| 24-06-24 | 3.4 | -12.37% | 50,003 |
Delayed Quote Nasdaq, June 28, 2024 at 01:48 pm EDT
More quotes
Qilian International Holding Group Ltd is a China-based company mainly engaged in the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives (TCMD) product, heparin product, sausage casings and fertilizers. The Company operates through three segments: Oxytetracycline & Licorice Products and TCMD segment, Fertilizer segment and Heparin Products and Sausage Casing segment. Its main brand is Qilian Shan. The Company principally operates its businesses within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-09-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.40% | 21.74M | |
| +56.59% | 819B | |
| -6.47% | 351B | |
| +18.10% | 329B | |
| +9.80% | 298B | |
| +16.57% | 242B | |
| +2.04% | 225B | |
| +13.31% | 217B | |
| +8.73% | 168B | |
| -2.90% | 158B |
- Stock Market
- Equities
- QLI Stock
